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Abstract
Friedreich ataxia (FRDA) is a debilitating and frequently fatal neurological disorder that is recessively inherited. It
belongs to the group of genetic disorders known as the Repeat Expansion Diseases, in which pathology arises
from the deleterious consequences of the inheritance of a tandem repeat array whose repeat number exceeds a
critical threshold. In the case of FRDA, the repeat unit is the triplet GAA￿TTC and the tandem array is located in the
first intron of the frataxin (FXN) gene. Pathology arises because expanded alleles make lower than normal levels of
mature FXN mRNA and thus reduced levels of frataxin, the FXN gene product. The repeats form a variety of
unusual DNA structures that have the potential to affect gene expression in a number of ways. For example, triplex
formation in vitro and in bacteria leads to the formation of persistent RNA:DNA hybrids that block transcription. In
addition, these repeats have been shown to affect splicing in model systems. More recently, it has been shown
that the region flanking the repeats in the FXN gene is enriched for epigenetic marks characteristic of
transcriptionally repressed regions of the genome. However, exactly how repeats in an intron cause the FXN mRNA
deficit in FRDA has been the subject of much debate. Identifying the mechanism or mechanisms responsible for
the FXN mRNA deficit in FRDA is important for the development of treatments for this currently incurable disorder.
This review discusses evidence for and against different models for the repeat-mediated mRNA deficit.
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Introduction
Friedreich ataxia (FRDA) (OMIM 229300; http://www.
omim.org/entry/229300), first described in 1863 by
Nikolaus Friedreich, is a relentlessly progressive disorder
caused by mutations in the frataxin (FXN) gene. It is the
most common heritable ataxia in Caucasians [1]. The
major pathological changes include loss of myelinated
axons in peripheral neurons, particularly in the dorsal
root ganglia, the degeneration of posterior columns of
the spinal cord and the loss of peripheral sensory nerve
fibers. Myocardial muscle fibers also degenerate and are
replaced by macrophages and fibroblasts. The net result
of these and other changes include not only limb and
gait abnormalities, but also hypertrophic cardiomyopa-
thy, limb muscle weakness, absent lower limb reflexes
and a positive extensor plantar response (Babinski sign).
Decreased vibration sense, skeletal abnormalities, dysar-
thria, and diabetes are common comorbid features.
Many symptoms become apparent during adolescence.
Loss of ambulation occurs roughly 15 years after disease
onset with > 95% of patients becoming wheelchair
bound by the age of 45. Early mortality due primarily to
cardiac failure is not uncommon [2,3].
The most common FRDA mutation is an expansion of the
GAA￿TTC repeat tract in intron 1 of the frataxin gene
FRDA is inherited in an autosomal recessive fashion.
The affected gene, frataxin (FXN) (OMIM 606829;
http://omim.org/entry/606829), is located on chromo-
some 9q13 in humans [4]. The first intron contains a
GAA￿TTC repeat tract embedded in the central poly(A)
tract of an AluSq element from which it probably arose
[5]. The GAA￿TTC repeat tract, which is located
approximately 1.3 kb downstream of the major FXN
transcription start site (TSS), is polymorphic in the
human population (Figure 1). While normal alleles have
between 8 to 33 repeats, most individuals with FRDA
have 2 FXN alleles each with > 90 repeats, the majority
having 600 to 900 repeats [4]. A minority of patients
(approximately 4%) are compound heterozygotes, having
one allele with > 90 repeats and a second allele with a
small deletion or point mutation in the FXN open read-
ing frame. No cases of individuals with deletions or
point mutations in both alleles are known [4].
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contains a large repeat expansion, FRDA is considered
to belong to a group of approximately 20 human genetic
disorders known as the Repeat Expansion Diseases. In
this group of diseases pathology arises from the conse-
quences of inheritance of alleles with repeat numbers
above a critical pathological threshold, which in the case
of FRDA is approximately 90 repeats. The basis of the
underlying expansion mutation responsible for these dis-
orders is unknown, and problems with DNA replication,
recombination and repair have all been suggested as
possible mechanisms [6].
FRDA results from a deficiency of FXN mRNA
Expansion results in FXN mRNA levels that are 4% to
29% of normal [7]. There is an inverse relationship
between repeat number and the amount of FXN mRNA
produced. The FXN gene product, frataxin, is a small,
highly conserved, acidic protein that is essential for life
[8]. It is highly expressed in the dorsal root ganglia, the
granular layer of the cerebellum as well as the heart,
pancreas, thymus, brown fat, muscle and liver. Although
the protein is nuclear encoded, it functions in the mito-
chondria where it is thought to be involved in the bio-
synthesis of iron-sulfur clusters (ISCs) [9], the
complexes that serve as prosthetic groups for a variety
of enzymes involved in energy and iron metabolism,
purine synthesis and DNA repair. However, its precise
role is currently unknown.
In principle, an FXN mRNA deficit could arise via an
effect of the intronic repeats on the efficiency of tran-
scription or some post-transcriptional event. However,
no difference has been seen in the decay rate for the
mature transcripts produced from normal and FRDA
alleles [10]. Thus, the FXN mRNA deficit presumably
results from events occurring at the level of transcrip-
tion, and/or pre-mRNA stability or processing.
The GAA￿TTC repeats form an intrinsic block to
transcription elongation in simple model systems
In vitro transcription of templates containing as few as
11 GAA￿TTC repeats produces less full-length RNA
than templates with no repeats [11]. The repeats form a
variety of unusual secondary structures under the same
conditions (Figure 2). These structures include purine:
purine:pyrimidine and pyrimidine:purine:pyrimidine tri-
plexes [11-15] and a related structure known as sticky
DNA [16]. It has been suggested that triplex formation
could affect transcription by sequestering transcription
factors or RNA polymerase (RNAP) [17,18]. It has also
been suggested that a pre-existing triplex or sticky DNA
blocks RNAP by making it more difficult for the tran-
scription complex to unwind the template [17].
However, whether the steady state levels of negative
superhelicity present in mammalian chromosomes are
high enough to allow the formation of such structures is
unclear. b-Alanine-linked pyrrole-imidazole polyamides
have been shown to bind GAA￿TTC tracts with high
Figure 1 The 5’ end of the frataxin (FXN) gene showing the minimal promoter, exon 1 and the promoter proximal end of intron 1.
TSS1 and TSS2 refer to transcription start sites described in two different studies. TSS1 was identified based on a cDNA clone isolated from
cardiac mRNA [4]. TSS2 is the major start site in lymphoblastoid cells identified by primer extension [52]. The positions of various interspersed
repeated sequences are indicated by the rectangles outlined with black dashed lines. The dotted black arrow indicates the estimated extent of
the FXN antisense transcript-1 (FAST-1) transcript based on nested PCR [25]. The solid black line superimposed on it is the region that could be
amplified by a single round of PCR. The larger antisense transcript includes an open reading frame (ORF) with a non-canonical Kozak sequence
whose significance is unknown. The ORF is intact in humans but truncated in closely related primates. Arrows indicate the location of the
binding sites for serum response factor (SRF), activator protein 2 (AP2) [73], CCCTC-binding factor (CTCF) [25], an early growth response protein 3
(EGR3)-like factor [73] and an E-box binding protein [48] which have been shown to be positive regulators of FXN expression.
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FXN expression in cells from individuals with FRDA [19].
This would be consistent with a role for sticky DNA in
FRDA. However, the specificity of these polyamides is
uncertain and thus, the molecular basis of their effect is
unclear.
In addition to preformed triplexes, there is also evi-
dence to suggest that triplexes formed during transcrip-
tion in vitro lead to the formation of an RNA:DNA
hybrid as illustrated in Figure 3[11,12,20]. This results
in a block to transcription and trapping of RNAP on the
template at the end of the repeat. Other sequences or
conditions that favor the formation of R-loops also
impede transcription [21,22]. Thus it is reasonable to
think that an R-loop on a FRDA allele, however it is
formed, could cause a block to transcription elongation.
Single-stranded nicks in the template, perhaps arising
from attempts to repair one of the structures formed by
the repeat, can also increase the likelihood that R-loops
will form during subsequent rounds of transcription
[ 2 3 ] .F u r t h e r m o r e ,w o r kin vitro suggests that R-loops
could also arise via bidirectional transcription through
the repeat [24]. An antisense transcript, FXN antisense
transcript-1 (FAST-1), has been identified in the FXN
gene that could potentially contribute to such hybrids
(see Figure 1). However, its 5’ end has not been mapped,
its concentration is low and it is unclear at this time
whether it includes the repeat [25].
While direct proof of the formation of an R-loop by the
FRDA GAA￿TTC repeats in mammalian cells is lacking,
other purine-rich repeats are known to do so [26]. In addi-
tion, the promoter distal end of the repeat in human
induced pluripotent cells generated from patient cells is
known to bind the mismatch repair proteins MSH2 and
MSH3 [27], which would be consistent with the formation
of an unusual DNA conformation of some sort at this
locus.
While a consistent inhibition of transcription elonga-
tion is seen with different RNAPs on naked DNA tem-
plates in vitro [11,12,16,28,29], conflicting results have
been seen with mammalian nuclear extracts and episomes
in yeast and mammalian cells [16,28,30-32]. Integrated
Figure 2 Examples of different structures formed by GAA￿TTC repeats showing their constituent hydrogen bonding schemes. (A) A
purine:purine:pyrimidine triplex [11,12]. This triplex involves Hoogsteen hydrogen bonding between a purine already in a Watson-Crick base pair
with a pyrimidine, and a purine from a different region of the repeat. (B) A GAA hairpin [61]. Various hydrogen bonding schemes involving G￿G,
G￿A and A￿A base pairs have been proposed [74] including the one shown. However, the precise molecular details of the GAA hairpin are
unknown. (C) A parallel duplex in which, unlike the antiparallel configuration of normal Watson-Crick duplex, the polarity of the two base-paired
strands is the same [75]. In this configuration the base pairs involve a reverse Watson-Crick orientation and two, rather than three, hydrogen bonds.
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and mouse models [33-35], but whether this effect is
mediated at the level of transcription elongation is unclear.
The GAA￿TTC repeats affect splicing in model systems
A so-called frataxin minigene construct, containing a
CMV promoter, the FXN exon 1, part of intron 1 and
all of exon 2, that was transfected into mammalian cells,
showed a decreased splicing efficiency when the GAA-
rich strand was transcribed but not the TTC-strand
[30]. It was thus suggested that the deficit of mature
FXN mRNA in FRDA results from aberrant mRNA spli-
cing in which intron 1 is retained. The aberrant splicing
seen with the minigene was attributed to the ability of
the repeats to bind splicing factors such as the serine/
arginine (SR)-rich protein family and the proteins het-
erogeneous nuclear ribonucleoprotein (hnRNP) A1 and
hnRNP A2 as outlined in Figure 4, although how bind-
ing of these factors would lead to intron retention is
unclear.
However, since total FXN mRNA abundance is
reduced in FRDA cells, any mis-spliced transcript would
have to be rapidly degraded for aberrant splicing to
account for the mRNA deficit, which was not the case
with the minigene tested [30]. In addition, the splicing
abnormalities in the frataxin minigene were context and
position dependent. This is important since in this con-
struct both the repeat context and position differed
from what is seen in the FXN locus.
The FRDA GAA￿TTC repeats have also been shown
to reduce splicing in yeast [36]. This effect was attribu-
ted to the increased length of the intron rather than any
specific effects of the repeat per se. In yeast the largest
known intron is < 1 Kb and in these organisms splicing
efficiency is related to intron length [37]. However,
many efficiently spliced human introns are much longer,
with the human genome containing > 3000 genes with
introns > 50 Kb. Since the FXN intron 1 of normal
alleles is already 11 Kb and cases of FRDA are apparent
with as few as 90 repeats, it seems unlikely that a
change in intron length per se, is responsible for the
reduced FXN expression in FRDA.
Furthermore, studies of transcripts produced from the
intact FXN gene did not detect any splicing abnormal-
ities in FRDA cells [10,28]. However, since the existence
of a very unstable splice isoform is difficult to defini-
tively exclude, this issue is still unresolved.
Expansion of the FRDA GAA￿TTC repeat tract also causes
epigenetic changes
While it has been known for some time that a subset of
Repeat Expansion Diseases are associated with hetero-
chromatin formation, notably those disorders arising
from CGG￿CCG repeat expansion such as fragile X syn-
drome (FXS) [38], the idea that the FRDA GAA￿TTC
repeats produce aberrant epigenetic modifications has
only recently been appreciated. In part, the possibility
that FRDA could be an epigenetic disorder was not
initially entertained since unlike the affected gene in
FXS, significant transcription still occurs from most
FRDA alleles and early thinking in the field was that
DNA methylation was required for epigenetic silencing
Figure 3 A triplex/RNA:DNA hybrid model for Friedreich ataxia
(FRDA) [11,12,20]. Transcription through the repeat leaves the non-
template purine-rich strand transiently unpaired. This strand can then
fold back and interact with the duplex that has already reannealed
behind the RNA polymerase (RNAP), thereby forming a triplex. Triplex
formation, in turn, leaves the pyrimidine-rich strand in the second half
of the repeat free to form a hybrid with the nascent RNA. This may be
facilitated by the particular stability of an RNA:DNA hybrid containing a
purine-rich RNA strand [76]. Evidence suggests that nucleation of this
hybrid leads to unwinding of the triplex and the formation of a long
persistent RNA:DNA hybrid that involves the whole repeat. The net
result is the formation of a stable R loop in which the pyrimidine
strand of the repeat is hybridized to the nascent transcript leaving the
purine-rich strand unpaired. The RNAP becomes trapped on the
template at the 3’ end of the repeat.
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dues, the only dinucleotide subject to significant methy-
lation in mammals, non-epigenetic mechanisms, like
those described earlier, initially received more attention.
However, it is now appreciated that even in those
repeat expansion diseases where the repeat has a high
density of CpG residues, such as FXS, DNA methylation
is probably not the first step in heterochromatinization
[44,45]. Furthermore, the expanded CTG￿CAG repeats
in myotonic dystrophy type 1 (DM1) are associated with
heterochromatin despite their lack of CpG residues [46].
In addition, work with transgenic mice containing
GAA￿TTC repeats or CAG￿CTG repeats showed that
the repeats conferred variegation in the expression of a
linked transgene, analogous to position effect variegation
(PEV) in Drosophila [47]. These observations suggested
that, despite the absence of methylatable residues, the
FRDA repeats might trigger the formation of hetero-
chromatin that could spread to adjacent sequences.
While the repeat itself cannot be methylated, DNA
methylation could potentially occur secondarily to other
chromatin changes in the region flanking the repeat.
Consistent with that idea, we have shown that while
DNA methylation is seen in the region flanking the
repeat on normal alleles, perhaps due to spreading from
adjacent Alu elements, more extensive DNA methyla-
tion is seen in this region in patient cells [33,48]. A
direct relationship between repeat length and the extent
of DNA methylation has also been found in patient cells
[49]. Since disease severity is related to repeat length, a
direct relationship between disease severity and DNA
methylation thus also exists.
Figure 4 Altered splicing model for Friedreich ataxia (FRDA) [30]. On unaffected frataxin (FXN) alleles the repeat is too short to significantly
impact splicing. However, once the repeat number exceeds 90, splicing factors that are normally involved in the proper splicing of the FXN
gene become mislocalized such that normal splicing is prevented. This could be the result of binding of splicing factors to the repeat,
preventing their normal assembly at the splice junctions. Alternatively, the unrestrained spread of these or other repeat-binding proteins, such as
heterogeneous nuclear ribonucleoprotein (hnRNP) A1 [77], could block access of factors needed for proper splicing analogous to what has been
proposed for HIV [78]. It may also be that the repeat sequesters serine/arginine (SR) proteins such as alternative splicing factor/splicing factor 2
(ASF/SF2). Since these proteins are is required for 5’ splice site selection and cleavage [79], this could lead to a local deficiency at the splice site
and thus the failure to efficiently remove intron 1.
Kumari and Usdin Clinical Epigenetics 2012, 4:2
http://www.clinicalepigeneticsjournal.com/content/4/1/2
Page 5 of 10Not only is DNA methylation more extensive on
FRDA alleles, but the methylation protection of 3 CpG
residues that is seen upstream of the repeat on unaf-
fected alleles is also lost [48]. One of these residues is
within an E-box site that is important for maximal pro-
moter activity in reporter assays in mouse myoblast
cells. However, plasmids that are specifically methylated
at this site do not show reduced transcription [48]. This
suggests that loss of factor binding does not occur sec-
ondarily to DNA methylation, but rather that protein
binding normally protects those CpG residues from
methylation. Thus, the loss of the normal methylation
‘footprint’ in FRDA cells likely reflects chromatin
changes that restrict access of these factors to their nor-
mal binding sites. Consistent with this view, FRDA
patient alleles have been shown to be enriched for a
variety of histone modifications characteristic of silenced
genes including hypoacetylated H3 and H4 and
dimethylation and trimethylation of histone H3 lysine 9
(H3K9) [48,50]. These histone modifications are highest
in the regions flanking the repeat [50-52].
Aberrant DNA methylation does not extend as far as
the promoter in any of the patient cell lines that have
been tested thus far. However, whether histone modifi-
cations extend into the promoter is still controversial.
The wide variation in the level of histone modifications
seen in normal cells, the use of FRDA cell lines with
very different repeat numbers and mRNA levels and dif-
ferences in the experimental design and data analysis
have added to the difficulty in reaching a consensus.
However, to date there have been a number of reports
of a histone profile typical of transcriptionally repressed
genes on the affected FXN promoter in lymphoblastoid
cells [25,52], the brains of affected individuals [33] and
in a cell culture model [35]. Enrichment of repressive
chromatin marks on the FXN promoter has also been
reported in the brain and heart in transgenic mice mod-
els of the disorder [33]. In addition, enrichment of the a
and g isoforms of heterochromatin protein 1 (HP1), a
non-chromosomal protein associated with heterochro-
matin, on the promoter and the loss of CCCTC-binding
factor (CTCF) binding to the promoter region in patient
cells lends support to the idea that epigenetic changes
originating in the repeat can spread to the 5’ end of the
FXN gene [25].
What is the basis of the epigenetic changes?
It has been suggested that the loss of CTCF binding is
responsible for the observed histone changes on FRDA
alleles [25]. However, this raises the question of what
leads to the loss of CTCF binding. Since heterochroma-
tin can be generated by the repeats embedded in a com-
pletely different sequence context [35,47] and levels of
the repressive histone modifications are highest in the
region of the FXN gene that includes the repeat [50-52],
it may be that the trigger for these epigenetic modifica-
tions is specifically related to some intrinsic property of
the repeat itself as has been suggested for FXS [53]. This
effect may be at the DNA level perhaps via the ability of
the repeat to bind proteins that then recruit silencing fac-
tors [54]. It could also be a consequence of the repair of
DNA damage occurring in the repeat [55-57]. An unu-
sual structure formed by the FRDA repeat may contri-
bute to this process if it were trigger the DNA damage
response. The binding of MSH2/MSH3 complexes to the
region containing the repeat in patient cells lends weight
to the idea that some sort of structure formed by the
repeat is recognized by the cell as a site of DNA damage
[27]. It is also possible that reduced transcription, result-
ing perhaps from a triplex/RNA:DNA hybrid formation,
leads to heterochromatic changes, as it does in some
plant genes by favoring the recruitment of H3K27 tri-
methylation (H3K27Me3) [58].
It could also be that heterochromatinization is RNA
dependent perhaps involving a long non-coding RNA
(lncRNA), as has been described for HOX genes and the
lncRNA HOTAIR [59]. The non-coding RNA could be
generated in cis or trans. Recent work has shown that the
formation of a DNA:RNA triplex between a chromoso-
mally located gene and ectopic RNA leads to enrichment
of the DNA with H4K20Me3 and subsequent gene silen-
cing [60]. Formation of such a triplex by the GAA￿TTC
repeat and either the repeat region in the sense or anti-
sense transcript could thus lead to heterochromatin
initiation within the repeat. Alternatively, if RNA con-
taining a large number of GAA repeats can form hairpin-
like GAA repeats in DNA [61], they may be source of
double-stranded (ds)RNA for the RNA interference
(RNAi) pathway. Transcripts containing the repeats may
thus enter the RNAi pathway as has been demonstrated
for the repeats responsible for FXS and DM1 [62,63].
How could these chromatin changes affect FXN
transcription?
Since the repeat-associated chromatin changes are located
in both the transcriptional unit and in the promoter of at
least some patient cells, they have, in principle, the poten-
tial to affect expression of the FXN gene in a number of
different ways. This effect could be exerted close to the
start of transcription mediated by chromatin changes on
the promoter. In addition, CTCF binding has been shown
to play an important role in FXN expression [25]. So, sim-
ply the loss of this factor from patient alleles could lead to
reduced rates of transcription. Furthermore, even in the
absence of altered promoter chromatin, histone and DNA
methylation changes in the intron that lead to loss of bind-
ing of important regulatory factors may affect transcrip-
tion initiation or early steps in elongation. Since DNA
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of transcription elongation [64], an effect on transcription
through the intron is also possible.
Do epigenetic changes account for the FXN mRNA deficit?
T h er o l eo fc h r o m a t i nc h a n g e si nc a u s i n gt h eFXN
mRNA deficit in FRDA is currently the subject of much
debate. Histone deacetylase inhibitors have been shown
to increase FXN expression in FRDA primary lympho-
cytes and the brain and heart of a knock-in mouse
model of the disorder [34,50]. The histone deacetylase,
HDAC3, has been identified as an important target of
these drugs [65]. The increase in FXN expression is
accompanied by an increase in histone acetylation on
FRDA alleles. However, it has been reported that while
the histone methyltransferase inhibitor BIX-01294
reduced the levels of H3K9 dimethylation and trimethy-
lation on FRDA alleles, no accompanying increase in
FXN transcription was seen. This has led to the sugges-
tion that epigenetic changes are not responsible for the
FXN deficit and that repeat expansion causes FRDA by
forming a structural block to transcription elongation
[10].
This idea would appear to be supported by the obser-
vation that phosphorylation of serine 5, a mark charac-
teristic of the initiating form of RNA polymerase II (Pol
II Ser5-P), is present at similar levels at TSS1 [10], a
transcription start site identified in early studies [4].
However, recent work has shown that the major TSS
(TSS2) used in lymphoblastoid cells, the cell type used
for these studies, is closer to the start of the FXN open
reading frame than previously thought [52]. This is rele-
vant since the initiating form of Pol II is typically found
to have a narrow distribution at or downstream of the
TSS [66]. When a region immediately downstream of
TSS2 was examined, reduced levels of the initiating
form of Pol II [52] as well as total Pol II [51] were seen
in FRDA patient cells. A reduced level of H3K4 tri-
methylation (H3K4Me3) was also seen the region in the
region immediately downstream of TSS2 in patient cells
[52]. Deposition of this histone mark occurs early in the
transcription cycle primarily on the first nucleosome
[67,68]. Trimethylation of H3K4 is thought to be
required for both recruitment of the basal transcription
machinery and for transcription initiation on genes that,
like FXN, lack a TATA box [69]. In other genes, deposi-
tion of this histone mark is thought to occur immedi-
ately downstream of the promoter in a manner
dependent on the levels of the initiating form of Pol II
[69,70]. In either event, the reduced level of H3K4Me3
seen on patient alleles suggests that a problem with
transcription from FRDA templates is apparent very
early in the transcription cycle, perhaps at the level of
polymerase recruitment or transcription initiation.
More recently it has been suggested that the reduced
levels of Pol II are not due to reduced initiation but to
reduced promoter proximal pausing [51]. This conclu-
sion was based on the fact that no difference was seen
in H3K4Me3 levels on unaffected and affected alleles at
the 5’ end of the gene. However, in this study the region
examined was upstream of what we now know to be the
major TSS, in a part of the promoter that also did not
show differences between affected and unaffected alleles
in earlier reports [10,52]. Since H3K4Me3 is highest on
nucleosomes immediately downstream of the TSS, the
lower levels of H3K4Me3 that were seen on patient
alleles just upstream of the repeat in the study of Kim et
al. [51], in fact lend support to the idea that early events
in transcription occurring prior to or during H3K4 tri-
methylation are abnormal in FRDA. However, further
work is needed to establish precisely what step or steps
are affected.
Whatever the cause of the reduced levels of Pol II on
FRDA alleles, the lower levels of H3K36 trimethylation,
a histone mark associated with transcription elongation,
in the promoter proximal region [10,51,52], supports the
idea that there is an effect of the repeat on transcription
very close to the TSS more than 1 kb upstream of the
repeat. Furthermore, the reduced levels of H3K79Me2,
another mark of transcription elongation, found
upstream of the repeat in patient cells [51], further
strengthens the idea that there is reduced transcription
in the region preceding the repeat.
This is not to say that there is not a problem with
transcription closer to the repeat as well. An additional
effect of repeat expansion on Pol II elongation is sug-
gested by the reduced accumulation of H3K36Me3
downstream of the repeat on FRDA alleles [10,51,52].
Whether this represents an effect of the histone changes
and DNA hypermethylation in the vicinity of the repeat
in patient cells or a chromatin-independent process
remains to be seen.
The relationship between GAA repeat number and the
extent of intron DNA methylation raises the possibility
that the epigenetic changes on smaller alleles may be
smaller than on larger alleles and less likely to extend
into the promoter. Thus the relative contribution of
promoter-proximal and promoter-distal events may vary
with repeat number.
Conclusions
An effect of the GAA￿TTC repeat on events occurring >
1k ba w a ya tt h eFXN promoter is difficult to reconcile
with an effect of aberrant splicing. It is also difficult to
reconcile with a direct effect of the formation of a tri-
plex/R-loop unless problems occurring in the repeat
lead to the buildup of stalled polymerases that stretches
back to the promoter. Therefore, perhaps the most likely
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repeat-mediated epigenetic changes generate a chroma-
tin configuration that is less permissive for early steps in
transcription as illustrated in Figure 5. That is that
FRDA is, at least in part, a disorder of epigenetic dysre-
gulation. The lack of an effect of BIX-01294 on FXN
mRNA yield can be reconciled with this idea, if histone
marks other than H3K9 methylation need to be
removed before a chromatin conformation permissive
for transcription is reestablished, as has been suggested
for a number of other repressed genes [71,72]. If this is
the case, it would suggest that histone deacetylase inhi-
bitors, which are currently in clinical trials for treating
FRDA, are probably acting on one of the direct causes
of the transcription deficit. Such a mechanism would
not necessarily preclude a role for triplexes/R-loops in
events occurring at the promoter if, as discussed earlier,
such structures contribute in some way to the formation
of heterochromatin.
Whether problems with Pol II elongation in the vici-
nity of the repeat are epigenetically mediated or arise
from a physical block to elongation like that formed by
triplex/R-loops also remains an open question, with
some data supporting a role for chromatin-mediated
events and some data favoring a chromatin-independent
mechanism. It may be that both mechanisms contribute
to the FXN mRNA deficit in some way and further
work will be necessary to understand the relative
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Figure 5 Diagrammatic representation of an epigenetic model for Friedreich ataxia (FRDA). Not shown to scale. Unaffected alleles are
aberrantly methylated in the region flanking the repeat. Nonetheless, the 5’ end of the gene is associated with histones that are enriched for
marks of active chromatin. In particular, acetylation of histone H3 and H4 is high. The net result is that the chromatin is open and permissive for
transcription. Transcription factors including serum response factor (SRF), activator protein 2 (AP2) [73] and CCCTC-binding factor (CTCF) [25]
associate with the 5’ end of the gene. An early growth response protein 3 (EGR3)-like factor binds to the 5’ end of intron 1 [73] and an E-box
binding protein [48] bind to the region immediately upstream of the repeat. Under these conditions transcription initiation and elongation takes
place normally. In contrast, FRDA alleles become associated with histones that are hypoacetylated and show more extensive DNA methylation in
the region flanking the repeat. The net effect of these and other histone changes is the formation of a compact chromatin configuration. This
reduces binding of transcription factors and both frataxin (FXN) transcription initiation and elongation are reduced. Loss of CTCF binding is
correlated with an increase in the amount of FXN antisense transcript-1 (FAST-1) RNA that is transcribed antisense to FXN, but how this relates to
silencing is unclear. TSS: transcription start site.
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